Amp Volatility Score
Catalyst Info & Data Links
TITLE: SG016 for COVID-19
EU Clinical Trials Register (2020-001023-14): A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNβ-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection (COVID-19)
WHAT IS THE NEXT CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
03-18-2020 Start trial of SNG001 in COVID-19 imminently
2010: Interferon-beta (IFNβ) Inhibits Infection Of A Lung Epithelial Cell Line With Novel Variant H1N1 (‘swine Flu’) Influenza Virus. In B25. H1N1, SEASONAL INFLUENZA AND OTHER VIRAL PNEUMONIA: CLINICAL AND MECHANISTIC INSIGHTS (pp. A2634-A2634). American Thoracic Society.
2010: Interferon Beta (IFN²) Is Equally Effective At Inhibiting Rhinovirus Infection In Primary Bronchial Epithelial Cells Of Long Term Smokers (with And Without COPD) And Younger Non-smoking Subjects. In D54. PNEUMONIA: BENCH TO BEDSIDE (pp. A6186-A6186). American Thoracic Society.
2011: Interferon Beta (ifn-Beta) Protects Asthmatic Primary Bronchial Epithelial Cells (PBEC) From Infection With Respiratory Syncytial Virus (RSV). In B58. NEW DRUGS FOR BAD BUGS: SUSCEPTIBILITY AND MECHANISMS OF ACTION (pp. A3364-A3364). American Thoracic Society.
2011: Up-Regulation Of Lung Antiviral Biomarkers Following Inhaled Delivery Of Interferon Beta (IFN-Beta) To Controlled Asthmatic Subjects. In B14. NOVEL TREATMENTS FOR LUNG INFECTIONS: MODULATING IMMUNE RESPONSES (pp. A2500-A2500). American Thoracic Society.
2012: The effects of interferon beta on cold-induced asthma exacerbations. European Respiratory Society Annual Congress
2012: Duration Of Protective Antiviral Effect Of Exogenous Interferon-² Against Rhinovirus Infection In Primary Bronchial Epithelial Cells From Patients With COPD. In B55. HOST DEFENSE IN PULMONARY INFECTION AND TUBERCULOSIS (pp. A3295-A3295). American Thoracic Society.
2014: Effect Of Inhaled SNG001 (Interferon-Beta 1a) On Sputum And Blood Antiviral And Inflammatory Biomarkers During A Respiratory Virus Infection In Asthmatic Subjects. In C105. ENVISIONING AND TESTING NEW THERAPEUTIC APPROACHES TO PNEUMONIA (pp. A5236-A5236). American Thoracic Society.
2011: Exogenous IFN-β has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus. Journal of Allergy and Clinical Immunology, 127(5), 1148-1154.
2014: The Effect of Inhaled IFN-b on Worsening of Asthma Symptoms Caused by Viral Infections. American Journal of Respiratory and Critical Care Medicine, 190(2), 145-154.
IV IFN beta - Faron Pharmaceuticals
MECHANISM OF ACTION / RATIONALE
Interferon beta (IFN-beta) is a naturally occurring protein, which orchestrates the body’s antiviral responses. There is evidence that deficiency in IFN-beta production by the lung could explain the enhanced susceptibility of these at-risk patient groups to developing severe lung disease during respiratory viral infections. Furthermore, viruses, including coronaviruses, have evolved mechanisms which suppress endogenous IFN-beta production, thereby helping the virus evade the innate immune system (learn more).
Updated by HC
#SNG, #SG016, #COVID-19
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post